Long-Term Valproate Prophylaxis in Refractory Affective Disorders

References

• Hippocrates: Epidemics
   Google Scholar
• Kraepelin E: Manic-Depressive Insanity and Paranoia. Edinburgh, Livingston, 1921
   Google Scholar
• Post RM: Introduction: Emerging perspectives on val-proate in affective disorders. J Clin Psychiatry 50 (3)(suppl):3-9, 1989
   Google Scholar
• Rickels K, Lipman RS, Fisher 5, et al: Is a double-blind clinical trial really double-blind? Psychopharmacolo-gia 16:329-326, 1970
   Google Scholar
• Baastrup PC, Schou M: Lithium as a prophylactic agent. Its effect against recurrent depressions and ma-nic-depressive psychosis. Arch Gen Psychiatry 16:162–172, 1967
   PubMed Web of Science ®Google Scholar
• Gualtieri TC, Hicks RE, Mayo JP, Schroeder SR: The persistence of stimulant effects in chronically treated children: Further evidence of an inverse relationship between drug effects and placebo levels of response. Psychopharmacology 83:44–47, 1934
   Google Scholar
• Quitkin FM, Rabkin JD, Markowitz JM, et al: Use of pattern analysis to identify true drug response. Arch Gen Psychiatry 44:259–264, 1987
   PubMed Web of Science ®Google Scholar
• Mellergard M, Rosenberg NK: Patterns of response during placebo treatment of panic disorder. Acta Psy-chiatr Scand 81:340–344, 1990
   PubMed Web of Science ®Google Scholar
• Quitkin FM, Rabkin JG, Stewart J'N, et al: Heteroge-neity of clinical response during placebo treatment. Am J Psychiatry 148:193–196, 1991
   Google Scholar
• Quitkin FM, McGrath PJ, Rabkin JG, et at: Different types of placebo response in patients receiving anti-depressants. Am J Psychiatry 148:197–203, 1991
   Google Scholar
• Dunner DL, Fleiss JL, Fieve RR: Lithium carbonate prophylaxis failure. Br J Psychiatry 129:40–44, 1976
   PubMed Web of Science ®Google Scholar
• Wehr TA, Goodwin FK: Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 36:555–559, 1979
   PubMed Web of Science ®Google Scholar
• Wehr TA, Goodwin FK: Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 144:1403–1411, 1987
   PubMed Web of Science ®Google Scholar
• Mattson A, Seltzer RL: MAO[-induced rapid cycling bipolar affective disorder in an adDlescent. Am I Psy-chiatry 138:677–679, 1981
   Google Scholar
• Wehr TA, Sack DA, Rosenthal NE, Cowdry RW: Rapid cycling affective disorder: Contributing factors and treatment responses in 51 F atients. Am I Psy-chiatry 145:179–184, 1988
   PubMed Web of Science ®Google Scholar
• Okuma T, Kishimoto A, Inoue K, et at: Anti-manic and prophylactic effects of carbainazepine in manic-depressive psychosis. A preliminary report. Folia Psy-chiatr Neurol Jpn 27:281–297, 1973
   Google Scholar
• Post RM, Uhde TM, Roy-Byrne PP, et al: Correlates of an antimanic response to carbamazepine. Psychia-try Res 21:71–83, 1987
   PubMed Web of Science ®Google Scholar
• Post RM, Uhde TM, Ballenger JC, et at: Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry 140:1602–1604, 1983
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Post RM: Carbamazepine in manic de-pressive illness: A new treatment. Am J Psychiatry 137:782–790, 1980
   PubMed Web of Science ®Google Scholar
• McElroy SL, Keck PE, Pope HG: Sodium Valproate: Its use in primary psychiatric disorders. J Clin Psy-chopharmacol 7:1:16–24, 1987
   Google Scholar
• Calabrese JR, Delucchi GA: Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar dis-order. Am J Psychiatry 147:431–434, 1990
   PubMed Web of Science ®Google Scholar
• McElroy SL, Keck PE, Pope HG: Valproate in the treat-ment of rapid-cycling bipolar disorder. J Clin Psycho-pharmacol 8:275–279, 1988
   PubMed Web of Science ®Google Scholar
• Dunner DL, Fieve RR: Clinical factors in lithium car-bonate prophylaxis failure. Arch Gen Psychiatry 30:229–233, 1974
   PubMed Web of Science ®Google Scholar
• Maj M, Pirozzi R, Kemali D: Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacology 98:535–538, 1989
   PubMed Web of Science ®Google Scholar
• Kishimoto A, Omura F, Inoue K, et al: Long-term prophylactic effects of carbamazepine in affective dis-order. Br J Psychiatry 143:327–331, 1983
   PubMed Web of Science ®Google Scholar
• Kishimoto A, Omura F, Inoue K, et al: A comparative study of carbamazepine and lithium for prophylaxis of bipolar affective disorder. Yonago Acta Med 29:76–90, 1986
   Google Scholar
• Ballenger JC, Post RM: Therapeutic effects of carba-mazepine in affective illness: A preliminary report. Commun Psychopharmacol 2:159–178, 1978
   PubMedGoogle Scholar
• Okuma T, Inanaga K, Otsuki S. et al: A preliminary double-blind study of the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psycho-pharmacology 73:95–96, 1981
   PubMed Web of Science ®Google Scholar
• Placidi GF, Lenzi A, Lazzerini F, et al: The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind three-year trial in 83 pa-tients. J Clin Psychiatry 47:490–494, 1986
   PubMed Web of Science ®Google Scholar
• Kishimoto A, Okuma T: Antimanic and prophylactic effects of carbamazepine in affective disorders. In Sha-gass C, et al (eds): Abstracts of 4th World Congress of Biological Psychiatry. Amsterdam, Elsevier, 1985
   Google Scholar
• Watkins SE, Callender K, Thomas DR, et al: The effect of carbamazepine and lithium on remission from af-fective illness. Br J Psychiatry 150:180–182, 1987
   PubMed Web of Science ®Google Scholar
• Bellaire W, Demich K, Stoll K-D: Carbamazepine ver-sus lithium in prophylaxis of recurrent affective dis-orders. Psychopharmacology 96(suppl):287, 1988
   Google Scholar
• Lusznat RM, Murphy DP, Nunn CMH: Carbamaze-pine vs. lithium in the treatment and prophylaxis of mania. Br J Psychiatry 153:198–204, 1988
   PubMed Web of Science ®Google Scholar
• Fawcett J, Kravitz HM: The long-term management of bipolar disorder with lithium, carbamazepine, and an-tidepressants. J Clin Psychiatry 46:58–69, 1985
   PubMed Web of Science ®Google Scholar
• Frankenburg FR, Tohen M, Cohen BM, Lipinski JF: Long-term response to carbamazepine: a retrospective study. J Clin Psychopharmacol 8:130–132, 1988
   PubMed Web of Science ®Google Scholar
• Post RM, Leverich GS, Rosoff AS, Altshuler LL: Car-bamazepine prophylaxis in refractory affective disor-ders: A focus on long-term follow-up. J Clin Psychopharmacol 10:318–327, 1990
   PubMed Web of Science ®Google Scholar
• Lambert P-A: Acute and prophylactic therapies of pa-tients with affective disorders using valpromide (Di-propylacetamide). In Emrich HM, Okuma T, Muller AA (eds): Anticonvulsants in Affective Disorders. Amsterdam, Excerpta Medica, 1984, pp 33–44
   Google Scholar
• Lambert PA, Venaud G: Utilisation du valpromide en therapeutique psychiatrique. L'Encephale 13:367–373, 1987
   PubMedGoogle Scholar
• Semadeni GW: Etude clinique de l'effect normothy-mique du dipropylacetamide. Acta Psychiatr BeIg 76: 458–466, 1976
   Google Scholar
• Brennan M, Sandyk R, Borsook D: Use of sodium valproate in the management of affective disorders: Basis and clinical aspects. In Emrich HM, Okuma T, Muller AA (eds): Anticonvulsants in Affective Dis-orders. Amsterdam, Excerpta Medica, 1984, pp 56–65
   Google Scholar
• Vencovsky E, Soucek K, Zatecka I: Comparison of side effects of lithium and dipropylacetamide (Depamide). Cesk Psychiatr 4:223–227, 1983
   Google Scholar
• Prasad AJ: The role of sodium valproate as an anti-manic agent. Pharmatherapeutica 4:6–7, 1984
   PubMedGoogle Scholar
• Emrich HM, Altmann Dose M, von Zerssen D: Ther-apeutic effects of GABA-ergic drugs in affective dis-orders; a preliminary report. Pharmacol Biochem Behav 19:369–372, 1983
   PubMed Web of Science ®Google Scholar
• Emrich HM, Dose M, von Zerssen D: The use of so-dium valproate, carbamazepine, and oxcarbazine in patients with affective disorders. J Affect Disord 8:243–250, 1985
   PubMed Web of Science ®Google Scholar
• Puzynski S, Klosiewicz L: Valproic acid amide in the treatment of affective and schizoaffective disorders. J Affect Disord 6:115–121, 1984
   Google Scholar
• Hayes SG: Long-term use of valproate in primary psy-chiatric disorders. J Clin Psychiatry 50 (3)(suppl):35-39, 1989
   Google Scholar
• McElroy SL, Keck PE, Pope HG, Hudson JI: Valproate in the treatment of rapid-cycling bipolar disorder. J Clin Psychopharmacol 8:275–279, 1988
   PubMed Web of Science ®Google Scholar
• Stein D, Avni J: Thyroid hormones in the treatment of affective disorders. Acta Psychiatr Scand 77:623–636, 1988
   PubMed Web of Science ®Google Scholar
• Cowdry RW, Wehr TA, Zis AP, Goodwin FK: Thyroid abnormalities associated with rapid-cycling bipolar ill-ness. Arch Gen Psychiatry 40:414–420, 1983
   PubMed Web of Science ®Google Scholar
• Hayes SG: Anticonvulsants in long-term psychiatric treatment. In Emerging Perspectives in Affective Dis-orders (Post RM, chair), presented at the 142nd annual meeting of the American Psychiatric Association, San Francisco, May 6, 1989
   Google Scholar
• Hayes SG, Goldsmith BK: Psychosensory symptom-atology in anticonvulsant-responsive psychiatric ill-ness. Ann Clin Psychiatry 3:27–35, 1991
   Google Scholar
• Akiskal HS, Rosenthal RH, Rosenthal TL, et al: Dif-ferentiation of primary affective illness from situa-tional, symptomatic, and secondary depressions. Arch Gen Psychiatry 36:635–643, 1979
   PubMed Web of Science ®Google Scholar
• Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62, 1960
   PubMed Web of Science ®Google Scholar
• Beck A, Ward CH, Mendelson M, et al: An inventory for measuring depression. Arch Gen Psychiatry 4:561–571, 1961
   PubMed Web of Science ®Google Scholar
• Squillace K, Post RM, Savard R, Erwin-Gorman M: Life charting of the longitudinal course of recurrent affective illness. In Post RM, Ballenger JC (eds): Neu-robiology of Mood Disorders. Baltimore; Williams & Wilkins, 1984, pp 38–59
   Google Scholar
• Roy-Byrne PP, Post RM, Uhde TW, et al: The longi-tudinal course of recurrent affective illness; life chart data from research patients at the NIMH. Acta Psy-chiatr Scand 71:5–34, 1985
   Google Scholar
• Post RM, Roy-Byrne PP, Uhde TW: Graphic repre-sentation of the life course of illness in patients with affective disorder. Am J Psychiatry 145:844–848, 1988
   PubMed Web of Science ®Google Scholar
• Endicott J, Spitzer RL, Fleiss JL, Cohen J: The global assessment scale. Arch Gen Psychiatry 33:766–771, 1976
   PubMed Web of Science ®Google Scholar
• Kubanek JL, Rowell RC: The use of dilantin in the treatment of psychotic patients unresponsive to other treatment. Dis Nerv Syst 7:47–50, 1946
   Google Scholar
• Monroe RR, Wise SP: Combined phenothiazine, chlordiazepoxide and primidone therapy for uncon-trolled psychotic patients. Am J Psychiatry 122:694–698, 1965
   Google Scholar
• Monroe RR: Anticonvulsants in the treatment of agression. J Nerv Men Dis 160:119–126, 1975
   PubMed Web of Science ®Google Scholar
• Satel SL, Nelson JC: Stimulants in the treatment of depression; a critical overview. J Clin Psychiatry 50:241–249, 1989
   PubMed Web of Science ®Google Scholar
• Prien RF, Kupfer DJ, Mansky PA, et al: Drug therapy in the prevention of recurrences in unipolar and bi-polar affective disorders. Arch Gen Psychiatry 41:1096–1104, 1984
   PubMed Web of Science ®Google Scholar
• Aronson T, et al: Clonazepam treatment of five lith-ium-refractory patients with bipolar disorder. Am J Psychiatry 146:77–80, 1989
   PubMed Web of Science ®Google Scholar
• TorteIla FC, Long JB, Holaday JW: Endogenous opioid systems: physiological role in the self-limitation of sei-zures. Brain Res 332:174–178, 1985
   Google Scholar
• Isaac L, Swanger J: Alteration of electroconvulsive threshold by cerebrospinal fluid from cats tolerant to electroconvulsive shock. Life Sci 33:2301–2304, 1983
   Google Scholar
• Tortella FC, Long JB: Characterization of opioid peptide-like anticonvulsant activii:y in rat cerebrospi-nal fluid. Brain Res 456:139–146, 1988
   Google Scholar
• Papez JW: A proposed mechanism for emotion. Arch Neurol Psychiatry 38:725–743, 1937
   Google Scholar
• Gonzalez-Heydrich J, Peroutka SJ: Serotonin receptor and reuptake sites: Pharmacologic significance. J Clin Psychiatry 51:4(suppl):5-12, 1990
   Google Scholar
• Yoshida K: Influences of bilateral hippocampal lesions upon kindled amygdaloid convulsive seizure in rats. Physiol Behav 32:123–126, 1984
   Google Scholar
• McNamara JO, Galloway MT, Rigsbee LC, Shin C: Evidence implicating substanstia nigra in regulation of kindled seizure threshold. J Neurosci 4:2410–2417, 1984
   Google Scholar
• Bortolotto ZA, ZZello LE, Turski L, Cavalheiro EA: Effects of 2-chloroadenosine on amygdaloid and hip-pocampal kindled seizures. Arch Int Pharmacodyn Ther 277:313–320, 1985
   Google Scholar
• Jenike MA, Baer L, Ballantine TH, et al: Cingulotomy for refractory obsessive-compulsive disorder. Arch Gen Psychiatry 48:548–555, 1991
   PubMed Web of Science ®Google Scholar
• Lovett LM, Shaw DM: Outcome in bipolar affective disorder after stereotactic tractotomy. Br J Psychiatry 151:113–116, 1987
   PubMed Web of Science ®Google Scholar
• Poynton A, Bridges PK, Bartlett .1R: Resistant bipolar affective disorder treated by stereotactic subcaudate tractotomy. Br J Psychiatry 152:354-358, 1988
   Google Scholar
• Albright PS, Burnham WM: Development of a new pharmacological seizure model: effects of anticonvul-sants on cortical- and amygdala-kindled seizures in the rat. Epilepsia 21:681-689, 19E0
   Google Scholar
• Post RM, Rubinow DR, Ballenger JC: Conditioning and sensitization in the longitudinal course of affective illness. Br J Psychiatry 149:191-2)1, 1986
   Google Scholar